Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

User Top Menu

Editors' Pick
Melamed E, Levy M, Waters PJ, Sato D K, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim H J, et al.
Neurol Neuroimmunol Neuroinflamm. 2015 Aug; 2(4):e134. Epub 2015 Jul 23. PMID: 26236760. Abstract

Comparative Effectiveness Research on the Treatment of Multiple Sclerosis: Request for Information from the Patient-Centered Outcomes Research Institute

Request For Information (RFI) Released: July 13, 2015
Information Due: July 27, 2015 
For more information, email: info@pcori.org
 
Opportunity Snapshot
The Patient Centered Outcomes Research Institute has released a request for information (RFI) to identify patient registries and research groups with established cohorts of patients for potential collaborative

MS TRIAL ALERT: Investigators Recruiting for Study of Oral Laquinimod in Primary-Progressive MS

Summary: Investigators at sites worldwide are recruiting 375 people with primary-progressive MS for a Phase 2 clinical trial comparing oral laquinimod (Teva Pharmaceuticals), an experimental compound that is believed to modify immune function, with inactive placebo in 375 people with primary-progressive MS.  The study is funded by Teva Pharmaceutical Industries Ltd.
 
Rationale: There are currently no disease-modifying therapies specifically approved for treating the primary-progressive form of MS.

MS Trial Alert: Investigators Recruiting 1200 People with Relapsing MS For Study of Oral RPC1063

Summary: Investigators worldwide are recruiting 1200 people with relapsing MS for a study testing the effectiveness of two different doses of the experimental oral therapy RPC1063 (Receptos, Inc.) versus Avonex® (interferon beta-1a, Biogen Inc.) at reducing the rate of relapses. The study, called the Sunbeam Study, is funded by Receptos, Inc.
 
Rationale: RPC1063 is a selective sphingosine 1-phosphate receptor modulator (similar to the mode of action of Gilenya® [fingolimod, Novartis International AG]).

Pages

Subscribe to Multiple Sclerosis Discovery Forum RSS